We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
This study examines the prevalence of diabetes mellitus among tuberculosis (TB) patients in Cotonou
This study assesses screening of patients with diabetes for TB in routine community health services
Diabetes mellitus increases the risk of tuberculosis (TB) by 3 times and adversely affects treatment outcomes for TB
An advisory panel working together with the DVLA providing expert advice with the aim of improving road safety.
A systematic review of the effectiveness of lifestyle interventions for the prevention of type 2 diabetes mellitus (T2DM) in routine practice.
This trial was conducted during routine outpatient department hours in a primary health care setting in Puducherry, India
Declaration at a Summit in Bali, organised by the Indonesian Ministry of Health, The Union and World Diabetes Foundation
Pre-diabetes mellitus (pre-DM) and DM increase the risk of developing tuberculosis (TB)
Thus study takes place in 4 middle-income countries
This study takes place in a public health care facilities in Sonipat District, Haryana State, India
The characteristics, diagnosis, management, surveillance and epidemiology of Pseudomonas aeruginosa.
You may need to tell DVLA if you have diabetes, depending on the treatment you're getting
This study supports the need for routine screening of all patients with TB for diabetes in Kenya
The authorisation holder for dapagliflozin has withdrawn the indication for type 1 diabetes mellitus. The removal of the type 1 diabetes indication is not due to any new safety concerns and the other indications of dapagliflozin are unchanged.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.